Compile Data Set for Download or QSAR
Report error Found 25 Enz. Inhib. hit(s) with all data for entry = 9584
TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | WIN-34276 | US9688638, Ketazocine | U...)
Affinity DataIC50: 5.60nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | WIN-34276 | US9688638, Ketazocine | U...)
Affinity DataIC50: 8.40nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US9688638, 4 | US9688638, 5 | US9688638, 6 | US108...)
Affinity DataIC50: 879nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475929(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-6...)
Affinity DataIC50: 2.38E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475928(Preparation of (2S,6R,11R)-3-(cyclopropylmethyl)-8...)
Affinity DataIC50: 2.68E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475930(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-8...)
Affinity DataIC50: 3.33E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475933(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-8...)
Affinity DataIC50: 6.08E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475932(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-6...)
Affinity DataIC50: 1.28E+4nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | WIN-34276 | US9688638, Ketazocine | U...)
Affinity DataKi:  1.30nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US9688638, 20 | US10081602, Example 20 | US1086518...)
Affinity DataKi:  2.86nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475934(Preparation of (2S,6R,11R)-8-((4-(2,5,8,11,14-pent...)
Affinity DataKi:  5nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US9688638, 20 | US10081602, Example 20 | US1086518...)
Affinity DataKi:  44.3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475934(Preparation of (2S,6R,11R)-8-((4-(2,5,8,11,14-pent...)
Affinity DataKi:  58.5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US9688638, 4 | US9688638, 5 | US9688638, 6 | US108...)
Affinity DataKi:  203nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US9688638, 24 | US10081602, Example 24 | US1086518...)
Affinity DataKi:  494nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475929(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-6...)
Affinity DataKi:  549nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475928(Preparation of (2S,6R,11R)-3-(cyclopropylmethyl)-8...)
Affinity DataKi:  619nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475930(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-8...)
Affinity DataKi:  769nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475939(Preparation of (1R,2S,6R,11R)-1-(2,5,8,11,14-penta...)
Affinity DataKi:  955nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US9688638, 23 | US10081602, Example 23 | US1086518...)
Affinity DataKi:  1.06E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475933(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-8...)
Affinity DataKi:  1.40E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US9688638, 24 | US10081602, Example 24 | US1086518...)
Affinity DataKi:  1.81E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475932(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-6...)
Affinity DataKi:  2.96E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM475939(Preparation of (1R,2S,6R,11R)-1-(2,5,8,11,14-penta...)
Affinity DataKi:  3.92E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US9688638, 23 | US10081602, Example 23 | US1086518...)
Affinity DataKi:  7.96E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/18/2021
Entry Details
Go to US Patent